CDKN2A and Familial prostate cancer: To the best of our knowledge, this is the first study to delineate the association between CDK4 rs2069502, p16INK4a rs11515, RB rs3092904 polymorphisms and prostate cancer risk, as well as their influence on corresponding mRNA levels.